Evidence map›Paper›PMID 42039199›Full record

ArticleFrontiers in immunology2026

Immunization with detoxified TNFα elicits neutralizing antibodies and ameliorates inflammatory shock and autoimmune arthritis in mice.

Wen-Ling Hsu, He Ren, Wei-Chiao Huang, Ramkumar T Annamalai, Yumiao Zhang, Jonathan F Lovell

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wen-Ling Hsu *Department of Biomedical Engineering, University at Buffalo, State University of New York, New York, NY, United States.
He Ren *School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin University, Tianjin, China.
Wei-Chiao HuangDepartment of Biomedical Engineering, University at Buffalo, State University of New York, New York, NY, United States.
Ramkumar T AnnamalaiDepartment of Biomedical Engineering, University at Buffalo, State University of New York, New York, NY, United States.
Yumiao ZhangSchool of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin University, Tianjin, China.
Jonathan F LovellDepartment of Biomedical Engineering, University at Buffalo, State University of New York, New York, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Tumor necrosis factor-⍺ (TNF⍺) is central to the pathogenesis of autoimmune and inflammatory diseases, and monoclonal antibody-based TNF⍺ inhibitors are amongst the most used biologics worldwide. As an alternative to exogenously administered antibodies, active immunization has been explored as a TNF⍺ neutralization strategy. Methods: We generated a murine TNF⍺ (mTNF⍺) Y87S point mutant expressed in Results: Liposome display of TNF⍺ elicited significantly higher levels of neutralizing antibodies following immunization. In mice, immunization improved survival in the lethal shock model and ameliorated clinical symptoms and joint inflammation in the CIA model. The Y87S mutation similarly detoxified hTNF⍺ constructs, which could also be effectively displayed on CoPoP liposomes. Immunization with hTNF⍺ induced high-titer anti-TNF⍺ IgG and serum neutralizing activity superior to other adjuvants. Discussion: These findings demonstrate that CoPoP-based TNF⍺ point mutant vaccines can safely induce high levels of functional TNF⍺-neutralizing antibodies. This strategy represents a potential low-cost alternative to current TNF-blocking biologics for the treatment of autoimmune diseases.

Indexed as

Antibodies, NeutralizingArthritis, ExperimentalAutoimmune DiseasesTumor Necrosis Factor-alphaAnimalsDisease Models, AnimalFemaleHumansImmunizationLiposomesMiceAntibodies, NeutralizingLiposomesTumor Necrosis Factor-alphaautoimmune diseaseinflammationliposomal vaccinenanoparticlesrheumatoid arthritistherapeutic vaccineTNFα

Identifiers

PMID42039199
PMCPMC13106428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.